Clinical advances in antibody-drug conjugates for hematological malignancies
An antibody-drug conjugate (ADC) is a targeted therapeutic drug composed of a monoclonal antibody linked to a small-molecule cytotoxic drug via a linker. Once administered, ADCs bind to tumor-specific antigens, forming ADC-antigen complexes, which are internalized through endocytosis. The linkers ar...
Saved in:
Main Authors: | TANG Sijie, MI Jianqing |
---|---|
Format: | Article |
Language: | zho |
Published: |
Editorial Office of Journal of Shanghai Jiao Tong University (Medical Science)
2024-12-01
|
Series: | Shanghai Jiaotong Daxue xuebao. Yixue ban |
Subjects: | |
Online Access: | https://xuebao.shsmu.edu.cn/article/2024/1674-8115/1674-8115-2024-44-12-1607.shtml |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
by: Yangyang Gao, et al.
Published: (2025-01-01) -
Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects
by: Yufei Wang, et al.
Published: (2025-02-01) -
Six events that shaped antibody approvals in oncology
by: Suman Paul, et al.
Published: (2025-02-01) -
A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity
by: Alyssa Synan, et al.
Published: (2025-12-01) -
EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
by: Bita Jafary, et al.
Published: (2025-01-01)